Mr. David E. Kerr

• 
  www.sec.gov/Archives/edgar/data/1464450/0001140361-10-0 - [Cached Version]
  Published on: 3/8/2010    Last Visited: 3/9/2010  

  0001464450 Kerr David E C/O PDI, INC., MORRIS CORPORATE CENTER 1 300 INTERPACE PARKWAY PARSIPPANY NJ 07054 0 1 0 0 Senior VP Business Development

• 
  painmanagement.improvingmyhealth.com/arc/comprehensive- - [Cached Version]
  Published on: 4/20/2009    Last Visited: 11/24/2009  

  PDI Appoints David E. Kerr Senior Vice President of Business . - Genetic Engineering News PDI, Inc. ( NASDAQ: PDII ), a pioneer in providing contract sales and commercialization services to the biopharmaceutical industry, announces the appointment of pharmaceutical executive David E. Kerr to the position of Senior Vice President of ...

• 
  phx.corporate-ir.net/phoenix.zhtml?c=123046&p=irol-news - [Cached Version]
  Published on: 12/6/2006    Last Visited: 9/27/2009  

  Additionally, the company announced that David E. Kerr has been promoted to Senior Vice President, Commercial Business, to head the sales and marketing efforts for the both branded and generic businesses.
  ...
  The company also announced that David Kerr has been promoted from Vice President, Business Development, to Senior Vice President, Commercial Business, replacing Mark Gossett, who resigned in October.
  ...
  In this role, Kerr will have responsibility for all aspects of Endo's commercial business operation and its sales and marketing organizations, including the company's 590-person sales force, where he will re-direct Endo's launch efforts on Opana(R) and Opana(R) ER, and prepare for the expected launch of Frova for the prevention of menstrual migraine in the second half of 2007. Endo's commercial portfolio is focused primarily in pain management and includes nine branded products, led by Lidoderm(R), Opana(R), Opana(R) ER, Frova(R), Synera(R), and Percocet(R)/Percodan(R) and its five-product generics business.
  
  Kerr, 48, joined Endo in 2001 when the company began a comprehensive licensing and acquisition strategy to build a sustainable product pipeline across all phases of the development process. He has played a key role in that effort, which has produced six strategic partnerships. In addition, Endo currently has five products in mid- to late-stage development.
  
  "During his time at Endo, Dave Kerr has been a driver behind our business development effort and has been intimately involved with our commercial business.
  ...
  Prior to joining Endo, Kerr held senior commercial positions at Knoll Pharmaceuticals, American Cyanamid, and DuPont Diagnostics. He earned an M.B.A. from the University of Delaware and holds a B.S. in Business from Penn State University.

• 
  www.sec.gov/Archives/edgar/data/1054102/0001140361-09-0 - [Cached Version]
  Published on: 6/22/2009    Last Visited: 6/24/2009  

  0001464450 Kerr David E C/O PDI, INC., SADDLE RIVER EXEC. CENTRE 1 ROUTE 17 SOUTH SADDLE RIVER NJ 07458 0 1 0 0 Senior VP Business Development

• 
  www.citizen-times.com/apps/pbcs.dll/article?AID=2007712 - [Cached Version]
  Published on: 12/16/2007    Last Visited: 12/16/2007  

  "We want to deliver a message to our employees to make a difference and to reward and celebrate success," said Dave Kerr, Endo's senior vice president for commercial business, as he hauled up a tractor trailer tire from the mud and threw it onto the pile.

• 
  phx.corporate-ir.net/phoenix.zhtml?c=123046&p=irol-news - [Cached Version]
  Published on: 12/6/2006    Last Visited: 7/17/2008  

  Additionally, the company announced that David E. Kerr has been promoted to Senior Vice President, Commercial Business, to head the sales and marketing efforts for the both branded and generic businesses.
  ...
  The company also announced that David Kerr has been promoted from Vice President, Business Development, to Senior Vice President, Commercial Business, replacing Mark Gossett, who resigned in October.
  ...
  In this role, Kerr will have responsibility for all aspects of Endo's commercial business operation and its sales and marketing organizations, including the company's 590-person sales force, where he will re-direct Endo's launch efforts on Opana(R) and Opana(R) ER, and prepare for the expected launch of Frova for the prevention of menstrual migraine in the second half of 2007.Endo's commercial portfolio is focused primarily in pain management and includes nine branded products, led by Lidoderm(R), Opana(R), Opana(R) ER, Frova(R), Synera(R), and Percocet(R)/Percodan(R) and its five-product generics business.
  
  Kerr, 48, joined Endo in 2001 when the company began a comprehensive licensing and acquisition strategy to build a sustainable product pipeline across all phases of the development process.He has played a key role in that effort, which has produced six strategic partnerships.In addition, Endo currently has five products in mid- to late-stage development.
  
  "During his time at Endo, Dave Kerr has been a driver behind our business development effort and has been intimately involved with our commercial business.
  ...
  Prior to joining Endo, Kerr held senior commercial positions at Knoll Pharmaceuticals, American Cyanamid, and DuPont Diagnostics.He earned an M.B.A. from the University of Delaware and holds a B.S. in Business from Penn State University.

• 
  commercial.chestertonhumberts.com/office/Taunton-Mansfi - [Cached Version]
  Published on: 6/8/2009    Last Visited: 7/11/2009  

  Stephen Richards, John Plimmer, David Kerr and Philip Greenway

• 
  - Healthcare Businesswomen’s Association – Awards... - [Cached Version]
  Published on: 1/1/2008    Last Visited: 1/16/2010  

  David Kerr, Senior Vice President, Commercial Business

• 
  BioNetwork 2006 - The Fourth Annual Pharmaceutical -... - [Cached Version]
  Published on: 8/21/2004    Last Visited: 11/3/2005  

  David KerrVP, Business DevelopmentENDO PHARMACEUTICALS
  
  David has been Vice President of Business Development at Endo Pharmaceuticals since 2001 when the Company began a comprehensive initiative to build its product pipeline through partnerships.Since that time, Endo has licensed or acquired 13 products in the Pain/CNS area.Prior to joining Endo, David held senior commercial positions at Knoll Pharmaceuticals, American Cyanamid, and Du Pont Diagnostics.
  ...
  David KerrVP, Business DevelopmentENDO PHARMACEUTICALS

Page:  1 2